Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T22:40:22.447Z.
Calculation as of: 2026-10-06T22:40:22.447Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f1b69e3b66f27443032d61e4b8b82fea4bf8ea9e73a5af38069dd33813f2151d
PEG RATIO
N/A
PEG RATIO AVG TTM
N/A
PEG RATIO AVG 3Y
N/A
PEG RATIO AVG 5Y
N/A
PEG RATIO AVG 10Y
N/A
PEG RATIO AVG 15Y
N/A
PEG RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$259.12M
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AC Immune S.A. (ACIU) | $256.47M | N/A | N/A | N/A | N/A |
| Anika Therapeutics, Inc. (ANIK)vs › | $255.88M | N/A | 1.36 | 0.90 | 0.77 |
| Palisade Bio, Inc. (PALI)vs › | $258.63M | N/A | N/A | N/A | N/A |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $259.12M | N/A | N/A | N/A | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.14M | N/A | N/A | N/A | N/A |
| Treace Medical Concepts, Inc. (TMCI)vs › | $259.49M | N/A | N/A | N/A | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $259.56M | N/A | 0.96 | 0.96 | 0.96 |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $261.27M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | N/A | N/A | N/A | N/A |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $262.92M | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PEG RATIO |
|---|---|
| 2020-05-04 | 0.41 |
| 2020-05-01 | 0.38 |
| 2020-04-30 | 0.39 |
| 2020-04-29 | 0.41 |
| 2020-04-28 | 0.40 |
| 2020-04-27 | 0.43 |
| 2020-04-24 | 0.44 |
| 2020-04-23 | 0.42 |
| 2020-04-22 | 0.42 |
| 2020-04-21 | 0.42 |
| 2020-04-20 | 0.42 |
| 2020-04-17 | 0.44 |
| 2020-04-16 | 0.42 |
| 2020-04-15 | 0.40 |
| 2020-04-14 | 0.42 |
| 2020-04-13 | 0.40 |
| 2020-04-09 | 0.39 |
| 2020-04-08 | 0.39 |
| 2020-04-07 | 0.38 |
| 2020-04-06 | 0.40 |
| 2020-04-03 | 0.42 |
| 2020-04-02 | 0.42 |
| 2020-04-01 | 0.40 |
| 2020-03-31 | 0.38 |